Biophan CEO Michael Weiner Commences European Financial Tour to Meet with Leading European Institutional Investors; CEO also to Attend Sachs Bloomberg Conference in Switzerland and Thieme Investment Conference in Spain
During his European visit, Mr. Weiner will also deliver presentations at two financial conferences to discuss Biophan's proprietary technology and strategic business initiatives with European investment professionals. First, he will be presenting at the Sachs Bloomberg 5th Annual Biotech in Europe Forum on October 4-5, to be held at the Swisshotel Zurich, in Zurich, Switzerland.
“This trip will give us an opportunity to meet with new institutional investors throughout Europe who are also interested in Biophan.”
In addition, Mr. Weiner has been invited to return for the second consecutive year to the Small Cap Conference at the Annual Thieme Alumni Reunion to deliver an updated presentation about Biophan's progress in the last year. The Thieme forum, a private gathering of leading fund managers, is scheduled to be held at the Rocamar Hotel, in Cadaques, Spain, October 7-8.
"Biophan has enjoyed significant visibility and strong support from European institutional investors during our developmental period," said Mr. Weiner. "This trip will give us an opportunity to meet with new institutional investors throughout Europe who are also interested in Biophan."
The 5th Annual Biotech in Europe Investor Forum is a high-profile event organized in association with Bloomberg L.P. and attended by an executive level audience of over 450 investors, fund managers and capital raising companies. The Forum includes roundtables on key industry and scientific developments as well as finance and investment trends. The program will feature leading speakers from the investment banking, financial management and venture capital communities.
The Small Cap Conference at the Annual Thieme Alumni Reunion is organized by well-known Wall Street investment fund manager Heiko Thieme.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol BTN. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.